HONG KONG – Hangzhou, China-based Adlai Nortye Biopharma Co. Ltd. said Tuesday it partnered with Novartis AG to obtain the worldwide rights to BKM-120 (buparlisib), a selective PI3K inhibitor, to treat head and neck cancer, adding one more lead product to the Chinese company's oncology pipeline.